NSE · SUNPHARMA.NS
Sun Pharmaceutical Industries Limited
₹1,761.00+₹3.50 (+0.2%)
Sun Pharmaceutical Industries Limited’s quoted price sits in the lower half of its reported 52-week range, 13.97% below the high.
Loading market information…
NSE · DIVISLAB.NS · INR
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 09:59 AM UTC. Cached market data; not a live quote.
One-year closing-price history · INR. Historical prices are not a forecast.
Divi's Laboratories Limited’s quoted price sits in the upper half of its reported 52-week range, 0.78% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Divi's Laboratories Limited’s forward annual dividend is ₹30.00 per share, paid annual. The forward yield is 0.31% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Divi's Laboratories Limited’s next earnings report is currently expected on Nov 7, 2026, with estimated earnings per share of ₹32.10. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Divi's Laboratories Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Divi's Laboratories Limited, established in 1990 and based in Hyderabad, India, operates globally in the production and distribution of generic active pharmaceutical ingredients (APIs), intermediate chemicals, and nutraceuticals. The company's market footprint encompasses India, the United States, Asia, Europe, and other international regions. In addition to its core product lines, Divi's offers bespoke synthesis services for APIs and intermediates. It also provides a diverse range of carotenoids and markets various vitamins, catering to the nutritional, pharmaceutical, food and beverage, and animal feed industries. The firm was formerly known as Divi's Research Center before rebranding to Divi's Laboratories Limited in 1994.
Latest available per-share figures in INR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:16 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q4 2025 | May 17, 2025 | ₹24.91+9.98% vs estimate | ₹25.86B+0.96% vs estimate |
|---|
| Q3 2025 | Feb 3, 2025 | ₹22.20+16.05% vs estimate | ₹23.19B+2.25% vs estimate |
|---|
| Q2 2025 | Nov 9, 2024 | ₹19.20+4.86% vs estimate | ₹23.54B+5.56% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
₹1,761.00+₹3.50 (+0.2%)
Sun Pharmaceutical Industries Limited’s quoted price sits in the lower half of its reported 52-week range, 13.97% below the high.
₹2,244.00+₹62.10 (+2.85%)
Laurus Labs Limited’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
₹1,345.00+₹9.60 (+0.72%)
Dr. Reddy's Laboratories Limited’s quoted price sits in the upper half of its reported 52-week range, 4.94% below the high.
₹1,358.00-₹7.60 (-0.56%)
Cipla Limited’s quoted price sits in the lower half of its reported 52-week range, 14.77% below the high.
₹1,659.90+₹15.10 (+0.92%)
Aurobindo Pharma Limited’s quoted price sits in the upper half of its reported 52-week range, 4.6% below the high.
₹1,989.90+₹17.20 (+0.87%)
Lupin Limited’s quoted price sits in the lower half of its reported 52-week range, 21.33% below the high.
₹1,926.20-₹4.30 (-0.22%)
Ipca Laboratories Limited’s quoted price sits in the upper half of its reported 52-week range, 5.49% below the high.
₹19,295.00-₹675.00 (-3.38%)
Neuland Laboratories Limited’s quoted price sits in the upper half of its reported 52-week range, 20.35% below the high.
